999 brand history,chinese brand products,999 brand reviews

三九

HUARUN 999 is a well-known brand specializing in over-the-counter (OTC) and traditional Chinese prescription medicines. It is a publicly listed company engaged in the research, development, production, sales, and related health services of pharmaceutical products. Its core products have a significant influence in the markets of cold, gastrointestinal, dermatological, and orthopedic medications.

HUARUN 999 Pharmaceutical Co., Ltd. (referred to as “HUARUN 999”) is a large state-owned pharmaceutical company mainly involved in the research, development, production, sales, and related health services of pharmaceutical products.

HUARUN 999’s predecessor was the Southern Pharmaceutical Factory established in Shenzhen in 1985. In 1999, a joint-stock company was formed with contributions from companies including Sanjiu Enterprise Group and Shenzhen Sanjiu Pharmaceutical Co., Ltd. On March 9, 2000, it was listed on the Shenzhen Stock Exchange (stock code 000999). In 2008, it officially became part of China Resources Group. In 2010, the company changed its name from “Sanjiu Pharmaceutical Co., Ltd.” to “HUARUN 999 Pharmaceutical Co., Ltd.”

HUARUN 999’s main business focuses on the CHC health consumer products and prescription drug fields, covering a wide range of areas with a rich product line. The CHC health consumer products business covers nearly 10 categories, including cold, dermatology, gastrointestinal, cough, orthopedics, pediatrics, etc. Its core products in the areas of cold, gastrointestinal, dermatology, pediatrics, vitamins and minerals, cough, and orthopedic medications hold a significant market share. The prescription drug business focuses on areas such as oncology, cardiovascular and cerebrovascular diseases, digestive system, orthopedics, and pediatrics, with multiple products ranking at the forefront of the domestic market.

HUARUN 999 currently has 23 products with annual sales exceeding 100 million yuan. The “999” brand is highly recognized by consumers and the pharmaceutical industry. HUARUN 999 has consistently emphasized research and development innovation, conducting research projects on products such as “Shenfu Injection,” “Honghua Injection,” “Canmai Injection,” “Xintailin,” and “Xuesaitong Soft Capsules (Lifulin).” Entering the “14th Five-Year Plan” period, HUARUN 999 continues to increase R&D investment, accelerate the construction of an innovation system, and gradually enhance its innovation capabilities based on its strategic direction. HUARUN 999 collaborates with the Shenzhen Bay Laboratory to promote clinical research related to the innovative anti-tumor drug QBH-196. Additionally, the establishment and operation of three research institutes for innovative drugs, traditional Chinese medicine, and health drugs aim to actively progress in new product project initiation, introduction, and product improvement areas. In 2021, the proportion of HUARUN 999’s R&D investment for new product development significantly increased. The company has 71 ongoing research projects, mainly focusing on strategic areas such as oncology, orthopedics, dermatology, respiratory, and anti-infection, combining imitation and innovation for product layout. Among these, a Class 1 innovative Chinese medicine, DZQE, which is introduced to alleviate menopausal symptoms in women, is undergoing preclinical preparation. The Class 1 small molecule targeted anti-tumor new drug, QBH-196, has progressed smoothly and entered Phase I clinical trials. The Class 2 new drug “Mitoxantrone Hydrochloride Injection for Tracing” (trade name: Futashu®) has obtained a “Drug Registration Certificate” and has been marketed. This product is approved for use as a tracing product for draining lymph nodes in thyroid surgery areas.

Against the backdrop of an ever-changing pharmaceutical industry environment, HUARUN 999 leads “high-quality development” through innovation. It insists on the dual-drive approach of brand and innovation, continuously undergoes innovation-led transformation and upgrades, strengthens brand and channel construction, increases innovation investment, improves operational quality and efficiency, solidifies its industry position, and achieves sustained business growth.

Looking ahead, HUARUN 999 will always remember its initial mission. Guided by the mission “caring for public health, creating a better life together,” it will move forward towards the goal of becoming a leader in China’s “mass pharmaceutical and health industry.” Through innovative application of both traditional Chinese and Western medical science and technology, it will focus on high-quality innovation, research and development, and intelligent manufacturing of medical and health products. It is committed to serving every member of Chinese families and becoming the top brand in China’s pharmaceutical and health industry.